Fraunhofer ITEM aims to protect man from health hazards in our industrialized world and to contribute to the development of novel therapeutic approaches. Focusing on lung and inhalation, Fraunhofer ITEM has pooled its expertise in three business units: In the business unit Drug Development, we develop and test novel medications against respiratory diseases. Scientific expertise covers manufacturing of biologics, preclinical and clinical development. The business unit Chemical Safety is dedicated to determining the risks from potentially harmful substances.
The business unit Translational Medical Engineering offers many years of experience in the development of medical devices. All business units offer regulatory support. Numerous test systems are available, including in-vitro, ex-vivo and in-vivo. Studies can be performed in compliance with GXP regulations. A Regensburg-based division is dedicated to personalized tumor therapy. Fraunhofer ITEM is one of 67 institutions of the Fraunhofer-Gesellschaft, Europe's leading organization for applied research.
GMP manufacturing of biopharmaceuticals for clinical trials:
Preclinical research and testing covering efficacy and safety:
Respiratory clinical trials:
Ex vivo models for lung diseases with precision-cut lung slices (PCLS)
Main features of respiratory diseases can be displayed ex vivo by using fresh lung tissue, so-called precision-cut lung slices (PCLS). PCLS contain epithelial cells, fibroblasts, smooth muscle cells, nerve fibers, and even immune cells such as antigen-presenting cells and T-cells. The tissue is fully viable. Cells in the tissue interact with each other, thereby reflecting the highly specialized function of the lung.
CLINICAL RESEARCH CENTER HANNOVER Early-phase and proof-of-concept unit
The CRC Hannover, which opened in 2014, maximizes benefits for patients by enabling leading academic experts to pool their expertise and collaborate. Our focus is on airway diseases such as asthma, allergic rhinitis, COPD, and interstitial lung diseases, in particular idiopathic pulmonary fibrosis.
(Hannover/Regensburg, Germany) Scientists of the Regensburg-based Project Group for Personalized Tumor Therapy (Fraunhofer ITEM/University of Regensburg) and colleagues from Icahn School of Medicine at Mount Sinai discovered new mechanisms of early metastatic spread in breast cancer. Results hav...| » Further reading
(Hannover, Germany) The Fraunhofer-Gesellschaft, on behalf of the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, has signed an asset transfer agreement with Takeda GmbH to exclusively transfer its Surfactant and Continuous Powder Aerosolization (CPA) program assets to Fraunh...| » Further reading
Fraunhofer Institute for Toxicology and Experimental Medicine ITEM
Phone: +49 495 1153500
Get in contact with German companies in 3 easy steps! With one single question you can reach all relevant German Pavilion exhibitors of your selected industrial branch.
Click here if you notice an image that violates copyright or privacy rights.